New guidance suggests that CMS may be ramping up Sunshine Act auditing activities, potentially resulting in monetary liability for noncompliant reporting entities.
After more than a decade of relative inactivity, the Centers for Medicare & Medicaid Services (CMS) has signaled that it may soon commence audits of reporting entities under the Sunshine Act.
The Sunshine Act, formally known as the federal Physician Payments Sunshine Act, requires group purchasing organizations (GPOs) and manufacturers of certain drugs and devices that are reimbursed by certain federal healthcare programs to annually report to CMS payments or other transfers of value they make to US-licensed physicians, teaching hospitals, and certain other US-licensed healthcare professionals, referred to as “covered recipients,” during the prior calendar year.
They also must report any ownership or investment interests held in the reporting entity by a U.S.-licensed physician or a member of his or her immediate family.1 Failure of reporting entities to timely and accurately report pursuant to the law may result in civil penalties.
The law first became effective in 2013, and since that time, the Department of Health and Human Services (“HHS”), CMS, the HHS Office of Inspector General (“OIG”), and their designees, have each retained authority to audit, inspect, investigate, and evaluate reporting entities’ compliance with the law.2 However, these government agencies have not historically exercised this auditing authority, citing a lack of finalized audit strategies and audit plans.3 There have been limited instances of publicly-disclosed Sunshine Act enforcement actions in the decade that has transpired since reporting first went into effect.
CMS is signaling a shift in its attention to Sunshine Act compliance initiatives. For example, beginning in 2021, CMS required reporting entities to track payments or other transfers of value provided to additional provider types, including physician assistants and nurse practitioners, among others. And, effective this calendar year, reporting entities must evaluate whether they qualify under CMS’ recently promulgated and expansive definition of “physician-owned distributorship(s)” (PODs), and, if so, self-identify as a POD on their annual reports.4
The annual reports CMS makes to Congress also demonstrate a more forceful approach to enforcement, including a gradual uptick in pre-demand letters and civil monetary penalties for non-compliance (Figure 1). These developments all coincide with the Agency’s request to increase its budget for the Open Payments program, including to support “ongoing operations and enhancements.”5
In November 2023, CMS updated its Open Payments FAQ guidance to include three new FAQs focused specifically on Sunshine Act audits, despite not having publicly reported the performance of any audits as of that date. The FAQs provide detailed insights into key audit issues and explain the following:
Taken together, these signal CMS' efforts to ramp up its Sunshine Act auditing of reporting entities.
Reporting entities should take note of the new guidance from CMS and use this opportunity to confirm their tracking and reporting practices align with the Sunshine Act’s detailed requirements. As the agency shifts its attention to Sunshine Act compliance, companies can take the following steps to prepare for potential audits, whether based on targeted or random selection criteria. These small but impactful measures can go a long way towards confirming compliance and facilitating an orderly process in the event a company is selected for audit by CMS:
By adopting these practical steps and others, reporting entities can reduce their risk of noncompliance and potential penalties and demonstrate their commitment to transparency and accountability in the healthcare industry. Importantly, these strategies can help make the audit process run smoother and more efficiently, if a company is chosen for an audit, thereby conserving company resources, avoiding distractions from day-to-day operations, and reducing the chances of attracting unwanted attention or scrutiny to matters involving transfers of value.
References
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Delivery and Disruption: Navigating a Changing Care Terrain
September 16th 2024The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.